Loading clinical trials...

Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib | Clinical Trials | Clareo Health

UNKNOWNNA

Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib

A Clinical Study on the Treatment of Paronychia Caused by Afatinib With Zanthoxylum Nitidum Tincture

NCT03908892•Guangzhou University of Traditional Chinese Medicine

Summary

This is a randomized control trial evaluating the efficacy of zanthoxylum nitidum tincture on preventing progression of paronychia caused by afatinib from grade 1 to grade 2/3. Enrolled participates will randomly receive original treatment or original treatment plus zanthoxylum nitidum tincture immersion of the sick nail(s).

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Pathologically or cytologically confirmed non-small cell lung cancer；
•2. Undergoing treatment with afatinib；
•3. With grade 1 paronychia；
•4. Age between 18 to 80 years old；
•5. Estimated life expectancy of more than months；
•6. With the written informed consent.

Exclusion Criteria

•1. Paronychia before afatinib treatment;
•2. Grade 2 or severer paronychia;
•3. Stop using afatinib or with reduced dose of afatinib;
•4. Currently diagnosed with severe encephalopathy or psychiatric disorders affecting patients ability of self expression.
•5. Has other legal, medical or ethical reasons that patients are not appropriate for clinical study.

Locations (1)

Guangdong Provincial Hospital of Chinese Medicine

Guangzhou, Guangdong, China

Key Dates

Start Date

June 12, 2019

Primary Completion Date

December 1, 2022

Completion Date

December 1, 2022

Last Updated

August 15, 2022

Enrollment

110

ESTIMATED participants

Conditions

Paronychia

Interventions

zanthoxylum nitidum tincture

DRUG

tetracycline ointment

DRUG

Contacts

Yanjuan Zhu, Dr

CONTACT

86 20 81887233 zyjsophy@gzucm.edu.cn

Yihong Liu, Dr

CONTACT

80 20 81887233 yihongl@gzucm.edu.cn

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933

Acneiform Eruption Due to ChemicalXerosis Cutis+1 more

View study

UNKNOWNPHASE3

Efficacy and Safety of Timolol for TKI Induced Paronychia

NCT06140186

Paronychia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 15, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions